SCHEMBL764136

SCHEMBL764136

COC(=O)/C(=C/c1ccc(Br)o1)NC(C)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.55
ALDH1A1 P00352 9/20 0.55
MEN1 O00255 8/20 0.55
GAA P10253 4/20 0.55
LMNA P02545 5/20 0.45
POLB P06746 8/20 0.43
MAPT P10636 7/20 0.43
RECQL P46063 3/20 0.43
TDP1 Q9NUW8 3/20 0.43
L3MBTL1 Q9Y468 3/20 0.43
BLM P54132 2/20 0.43
APEX1 P27695 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CTDSP1 Q9GZU7 1/20 0.43
KDM4E B2RXH2 4/20 0.40
IDO1 P14902 1/20 0.39
HPGD P15428 2/20 0.38
HTT P42858 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5870043 1.00 KMT2A (0.55) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL5870048 1.00 KMT2A (0.55) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL762458 0.83 KMT2A (0.54) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL16065053 0.82 KMT2A (0.53) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL764134 0.82 KMT2A (0.53) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL28216579 0.75 KMT2A (0.46) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL8430294 0.74 MEN1 (0.47) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL8430296 0.74 MEN1 (0.47) KMT2AALDH1A1MEN1LMNAMAPT
SCHEMBL8653650 0.74 KMT2A (0.46) KMT2AALDH1A1MEN1GAALMNA
SCHEMBL2153050 0.72 LY96 (0.44) KMT2AALDH1A1MEN1GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138168-B1 Renin inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-20 US disclosed
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof MILLENNIUM PHARMACEUTICALS, INC. 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082496-A1 ACE-2 modulating compounds and methods of use thereof ACE, ACE2, AGTR2 KMT2A 1880/4885ALDH1A1 1305/4885MEN1 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.